Kymera Therapeutics Set to Announce Q4 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: seekingalpha
- Earnings Announcement: Kymera Therapeutics (KYMR) is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of -$0.79, reflecting a 10.2% year-over-year improvement, indicating slight progress in profitability.
- Strong Revenue Expectations: The anticipated Q4 revenue of $14.8 million represents a 100% year-over-year increase, showcasing significant growth in market demand and product sales, which could positively impact the stock price.
- Performance Forecast Changes: Over the past year, KYMR has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting growing market confidence in its performance, although there is still room for improvement.
- Valuation and Financing Dynamics: Kymera recently completed a $602 million public offering at $86.00 per share and proposed an additional $500 million fundraising plan, reflecting market recognition of its future growth potential while providing necessary funding for R&D and operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KYMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KYMR
Wall Street analysts forecast KYMR stock price to rise
22 Analyst Rating
21 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.460
Low
90.00
Averages
116.30
High
138.00
Current: 81.460
Low
90.00
Averages
116.30
High
138.00
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Purcell & Lefkowitz Investigates Kymera Therapeutics for Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Kymera Therapeutics to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder rights.
- Shareholder Rights Protection: The investigation focuses on safeguarding Kymera Therapeutics shareholders, ensuring they are informed about their rights and options, with the law firm offering free consultations to assist shareholders in addressing potential legal issues.
- Law Firm Background: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide in cases of securities fraud, breaches of fiduciary duty, and other corporate misconduct, highlighting its expertise in protecting shareholder interests.
- Contact Information: Shareholders seeking more information can visit the law firm's website or directly contact an attorney to ensure timely access to legal support and advice related to the case.
See More
Key Wall Street Rating Changes Overview
- LCI Industries Upgrade: Roth upgrades LCI Industries from Hold to Buy with a price target of $164, unchanged, following outsized Q1 EPS, indicating strong profitability that is expected to drive stock price upward.
- VF Corp Upgrade: BTIG raises VF Corp's rating from Neutral to Buy, citing more reasonable estimates reflecting positive outlook for Vans brand, which could enhance market confidence and shareholder returns.
- DaVita's Strong Performance: Deutsche Bank upgrades DaVita from Hold to Buy after reporting Q1 revenues of $3.415 billion, beating consensus by 2.2%, and EPS of $2.87, exceeding expectations by 22.1%, showcasing robust treatment growth and revenue per treatment.
- Monster Beverage Upgrade: Rothschild & Co Redburn upgrades Monster Beverage from Neutral to Buy, highlighting significant international growth potential as the company currently holds only 14% market share, suggesting substantial future market position improvement.
See More
Kymera Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: CEO Nello Mainolfi stated that Kymera's KT-621 BROADEN2 study is on track to complete enrollment this year, with data expected by mid-2027, which will lay the groundwork for market expansion in dermatological conditions.
- Collaboration Revenue Surge: The company reported collaboration revenue of $34.4 million in Q1, significantly exceeding analysts' expectations of $8.22 million, reflecting strong performance from the Gilead partnership, with an anticipated $45 million to be recognized in Q2 2026.
- R&D Spending Overview: R&D expenses for the quarter totaled $98.2 million, while G&A expenses were $20.4 million; although G&A growth is expected to moderate in the coming quarters, the effectiveness of R&D investments remains a key focus.
- Cash Flow and Financial Health: Kymera ended March with a cash balance of $1.55 billion, providing a runway into 2029, indicating strong financial health and potential for future growth.
See More
Kymera Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Announcement Date: Kymera Therapeutics (KYMR) is set to announce its Q1 2023 earnings on April 30 before market open, with a consensus EPS estimate of -$0.86, reflecting a 4.9% year-over-year decline, which may negatively impact investor sentiment.
- Revenue Expectations Decline: The expected revenue for Q1 is $8.23 million, representing a significant 62.8% year-over-year drop, indicating major challenges in revenue growth that could affect future financing and R&D capabilities.
- Performance Forecast Revisions: Over the past year, KYMR has beaten EPS estimates 75% of the time, while only achieving a 50% success rate for revenue estimates, highlighting uncertainties in meeting market expectations that could undermine shareholder confidence.
- Future Outlook: Despite current challenges, Kymera plans to present Phase IIb data for KT-621 in 2027, with a cash runway extending into 2029, demonstrating the company's long-term commitment to R&D and potential market opportunities.
See More
Kymera's KT-621 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Kymera Therapeutics' KT-621 has received Fast Track designation from the FDA for treating moderate to severe eosinophilic asthma, which will expedite the drug's market entry and enhance the company's competitive position in the respiratory disease sector.
- Clinical Trial Progress: KT-621 is currently being evaluated in two Phase 2b studies, including the BREADTH trial for eosinophilic asthma, with data expected by late 2027, providing critical evidence for the drug's efficacy and safety.
- Dermatology Research: Additionally, Kymera is conducting the BROADEN2 Phase 2b trial for moderate to severe atopic dermatitis, with results anticipated by mid-2027, further enriching the company's product pipeline and expanding market opportunities.
- Stock Price Fluctuation: Despite the FDA designation, Kymera Therapeutics' shares closed at $85.05 on Friday, down 2.63%, indicating a cautious market sentiment regarding the company's future performance, which may affect investor confidence.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Purcell & Lefkowitz Investigates Kymera Therapeutics for Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Kymera Therapeutics to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder rights.
- Shareholder Rights Protection: The investigation focuses on safeguarding Kymera Therapeutics shareholders, ensuring they are informed about their rights and options, with the law firm offering free consultations to assist shareholders in addressing potential legal issues.
- Law Firm Background: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide in cases of securities fraud, breaches of fiduciary duty, and other corporate misconduct, highlighting its expertise in protecting shareholder interests.
- Contact Information: Shareholders seeking more information can visit the law firm's website or directly contact an attorney to ensure timely access to legal support and advice related to the case.
See More
Key Wall Street Rating Changes Overview
- LCI Industries Upgrade: Roth upgrades LCI Industries from Hold to Buy with a price target of $164, unchanged, following outsized Q1 EPS, indicating strong profitability that is expected to drive stock price upward.
- VF Corp Upgrade: BTIG raises VF Corp's rating from Neutral to Buy, citing more reasonable estimates reflecting positive outlook for Vans brand, which could enhance market confidence and shareholder returns.
- DaVita's Strong Performance: Deutsche Bank upgrades DaVita from Hold to Buy after reporting Q1 revenues of $3.415 billion, beating consensus by 2.2%, and EPS of $2.87, exceeding expectations by 22.1%, showcasing robust treatment growth and revenue per treatment.
- Monster Beverage Upgrade: Rothschild & Co Redburn upgrades Monster Beverage from Neutral to Buy, highlighting significant international growth potential as the company currently holds only 14% market share, suggesting substantial future market position improvement.
See More
Kymera Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: CEO Nello Mainolfi stated that Kymera's KT-621 BROADEN2 study is on track to complete enrollment this year, with data expected by mid-2027, which will lay the groundwork for market expansion in dermatological conditions.
- Collaboration Revenue Surge: The company reported collaboration revenue of $34.4 million in Q1, significantly exceeding analysts' expectations of $8.22 million, reflecting strong performance from the Gilead partnership, with an anticipated $45 million to be recognized in Q2 2026.
- R&D Spending Overview: R&D expenses for the quarter totaled $98.2 million, while G&A expenses were $20.4 million; although G&A growth is expected to moderate in the coming quarters, the effectiveness of R&D investments remains a key focus.
- Cash Flow and Financial Health: Kymera ended March with a cash balance of $1.55 billion, providing a runway into 2029, indicating strong financial health and potential for future growth.
See More
Kymera Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Announcement Date: Kymera Therapeutics (KYMR) is set to announce its Q1 2023 earnings on April 30 before market open, with a consensus EPS estimate of -$0.86, reflecting a 4.9% year-over-year decline, which may negatively impact investor sentiment.
- Revenue Expectations Decline: The expected revenue for Q1 is $8.23 million, representing a significant 62.8% year-over-year drop, indicating major challenges in revenue growth that could affect future financing and R&D capabilities.
- Performance Forecast Revisions: Over the past year, KYMR has beaten EPS estimates 75% of the time, while only achieving a 50% success rate for revenue estimates, highlighting uncertainties in meeting market expectations that could undermine shareholder confidence.
- Future Outlook: Despite current challenges, Kymera plans to present Phase IIb data for KT-621 in 2027, with a cash runway extending into 2029, demonstrating the company's long-term commitment to R&D and potential market opportunities.
See More
Kymera's KT-621 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Kymera Therapeutics' KT-621 has received Fast Track designation from the FDA for treating moderate to severe eosinophilic asthma, which will expedite the drug's market entry and enhance the company's competitive position in the respiratory disease sector.
- Clinical Trial Progress: KT-621 is currently being evaluated in two Phase 2b studies, including the BREADTH trial for eosinophilic asthma, with data expected by late 2027, providing critical evidence for the drug's efficacy and safety.
- Dermatology Research: Additionally, Kymera is conducting the BROADEN2 Phase 2b trial for moderate to severe atopic dermatitis, with results anticipated by mid-2027, further enriching the company's product pipeline and expanding market opportunities.
- Stock Price Fluctuation: Despite the FDA designation, Kymera Therapeutics' shares closed at $85.05 on Friday, down 2.63%, indicating a cautious market sentiment regarding the company's future performance, which may affect investor confidence.
See More
